Review assessing whether small molecule (non-peptide) GLP-1 receptor agonists could become first-line treatments for type 2 diabetes, in the context of injectable GLP-1 agonists like semaglutide and retatrutide dominating the field. Discusses the pharmacological advantages and challenges of oral small molecule GLP-1R agonists, their potential to democratize access, and how they compare to the peptide agonists for glucose lowering and weight loss.
Seetharaman, Rajmohan; Pandit, Swarnima